Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.31% is 96% below its 5-year average of 7.60%, near the low end of its 5-year range (0.31%–8.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 93.14% below its 12-month average of 4.56%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.31%.
DEBT TO ASSETS RATIO
0.31%
DEBT TO ASSETS RATIO AVG TTM
4.56%
DEBT TO ASSETS RATIO AVG 3Y
8.08%
DEBT TO ASSETS RATIO AVG 5Y
7.60%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-93.14%
CURRENT VS 3Y AVG
-96.13%
CURRENT VS 5Y AVG
-95.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 775 covered companies
CURRENT VS SECTOR MEDIAN
+247.47%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$737.79M
Debt to Assets Ratio
0.31%
TTM Avg
4.56%
3Y Avg
8.08%
5Y Avg
7.60%
Market Cap
$736.37M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$735.04M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$719.97M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$758.23M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$715.65M
Debt to Assets Ratio
0.40%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$765.97M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$709.26M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$767.66M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $737.79M | 0.31% | 4.56% | 8.08% | 7.60% |
| Candel Therapeutics, Inc. (CADL)vs › | $736.37M | 0.24% | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | 0.08% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $719.97M | 0.06% | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $758.23M | 0.01% | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $715.65M | 0.40% | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $765.97M | 0.24% | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $709.26M | 0.00% | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $767.66M | 0.03% | N/A | N/A | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $705.96M | 0.00% | N/A | N/A | N/A |
Debt/Assets
0.3%
Debt/Equity
0.00
Current Ratio
19.69
Interest Coverage
-696.5x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.31% |
| 2026-03-31 | 0.51% |
| 2025-12-31 | 6.59% |
| 2025-09-30 | 7.33% |
| 2025-06-30 | 8.05% |
| 2025-03-31 | 8.38% |
| 2024-12-31 | 8.48% |
| 2024-09-30 | 8.39% |
| 2024-06-30 | 8.44% |
| 2024-03-31 | 8.45% |
| 2023-12-31 | 8.35% |
| 2023-09-30 | 8.29% |
| 2023-06-30 | 8.11% |
| 2023-03-31 | 7.18% |
| 2022-12-31 | 6.79% |
| 2022-09-30 | 6.52% |
| 2022-06-30 | 6.29% |
| 2022-03-31 | 6.05% |
| 2021-12-31 | 1.54% |
| 2021-09-30 | 0.56% |
| 2021-06-30 | 0.34% |
| 2021-03-31 | 0.39% |
| 2020-12-31 | 3.20% |
| 2020-09-30 | 55.41% |
| 2019-12-31 | 1319.23% |
